February 17, 2020
Eisai is voluntarily withdrawing its obesity treatment Belviq (lorcaserin) from the US market and discontinuing its sales at the request of the FDA, which found the drug’s elevated cancer risks versus placebo in an outcome study. The company’s US subsidiary,...read more